RE:RE:RE:New presentation up - realistic review.I was surprised to see in the presentation that there were still 165 employees at THTX. I would have thought the number would have moved down due to early cost-cutting and some employees moving on to other jobs. It looks like Paul's executive assistant has moved on as they are looking to fill that position.
While it is not much fun to look at a THTX corporate presentation with cancer at the end of it, it is a good presentation for what the company now looks like. The new data on the market sizes of Egrifta and Trogarzo is helpful and seems more reasonable that forecasts from years back. Hopefully, the indication that doctors may tie GILD's new drug together with Trogarzo is accurate as that could really help promote Trogarzo sales.
You are right that we are left with a growing legacy drug business selling very cheaply and two short term, low probability, wild cards in NASH and cancer. Since those wild cards are low probability, no one is paying up for them now but should either come to fruition, the stock would have a nice bounce. I think we will know the outcome of those wild cards in the next few months so we will not likely have to wait long to see if there is something there. I expect cancer to be effectively shelved for now but Egrifta has a chance of finally rewarding Dr. Grinspoon and THTX's many efforts to make it relevant in NASH on the back of the MDGL news.
SABBOBCAT wrote: They are doing what they can and have clearly highlighted the opportunities for partners. Essentially what it boils down to is, they have a plan to grow revenues and lean on the commercial side to try and get an appropriate valuation, but the only quick wins will come from securing partnerships.
So the investment thesis is, buy now with a path to growth and limited downside, plus a two free lottery tickets for your trouble.